AR102239A1 - Anticuerpos anti-ox40 humanizados y sus usos - Google Patents

Anticuerpos anti-ox40 humanizados y sus usos

Info

Publication number
AR102239A1
AR102239A1 ARP150103284A ARP150103284A AR102239A1 AR 102239 A1 AR102239 A1 AR 102239A1 AR P150103284 A ARP150103284 A AR P150103284A AR P150103284 A ARP150103284 A AR P150103284A AR 102239 A1 AR102239 A1 AR 102239A1
Authority
AR
Argentina
Prior art keywords
seq
antibody
fragment
hfw4
hfw3
Prior art date
Application number
ARP150103284A
Other languages
English (en)
Inventor
Damschroder Melissa
Du Qun
Oberst Michael
Hammond Scott
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of AR102239A1 publication Critical patent/AR102239A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo caracterizado porque comprende una región variable de cadena pesada (VH) humanizada y una región de cadena liviana variable (VL) humanizada; en donde la VH comprende una secuencia de aminoácidos con la fórmula: HFW1-HCDR1-HFW2-HCDR2-HFW3-HCDR3-HFW4, en donde HFW1 es la SEQ ID Nº 6 o la SEQ ID Nº 7, HCDR1 es la SEQ ID Nº 8, HFW2 es la SEQ ID Nº 9, HCDR2 es la SEQ ID Nº 14, SEQ ID Nº 15 o la SEQ ID Nº 16, HFW3 es la SEQ ID Nº 17, HCDR3 es la SEQ ID Nº 25, SEQ ID Nº 26, o la SEQ ID Nº 27, y HFW4 es la SEQ ID Nº 28; en donde la VL comprende la secuencia de aminoácidos SEQ ID Nº 29 o la SEQ ID Nº 32; y en donde el anticuerpo o fragmento del mismo se puede unir específicamente a OX40 humano. Reivindicación 42: Una composición caracterizada porque comprende el anticuerpo o fragmento del mismo de cualquiera de las reivindicaciones 1 a 41, y un transportador. Reivindicación 43: Un polinucleótido caracterizado porque comprende un ácido nucleico que codifica para el anticuerpo o fragmento del mismo, de cualquiera de las reivindicaciones 1 a 41, o una sudunidad polipeptídica del anticuerpo o fragmento del mismo de cualquiera de las reivindicaciones 1 a 41. Reivindicación 47: Un método para producir un anticuerpo o fragmento del mismo, caracterizado porque comprende cultivar la célula huésped de la reivindicación 46 bajo condiciones en donde se expresa el anticuerpo o fragmento del mismo codificado por el polinucleótido, y recuperar el anticuerpo o fragmento del mismo. Reivindicación 59: Un método para tratar cáncer en un sujeto, caracterizado porque comprende administrar a un sujeto en necesidad de tratamiento una cantidad eficaz del anticuerpo o fragmento del mismo de cualquiera de las reivindicaciones 1 a 41 o la composición de la reivindicación 42.
ARP150103284A 2014-10-10 2015-10-09 Anticuerpos anti-ox40 humanizados y sus usos AR102239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062431P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
AR102239A1 true AR102239A1 (es) 2017-02-15

Family

ID=55130798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103284A AR102239A1 (es) 2014-10-10 2015-10-09 Anticuerpos anti-ox40 humanizados y sus usos

Country Status (19)

Country Link
US (3) US9738723B2 (es)
EP (1) EP3204422B1 (es)
JP (2) JP6794348B2 (es)
KR (1) KR20170064550A (es)
CN (1) CN107074953A (es)
AR (1) AR102239A1 (es)
AU (1) AU2015328090A1 (es)
BR (1) BR112017007170A2 (es)
CA (1) CA2963798A1 (es)
CL (1) CL2017000885A1 (es)
CO (1) CO2017004516A2 (es)
ES (1) ES2914177T3 (es)
GB (1) GB2536324A (es)
IL (1) IL251537A0 (es)
MX (1) MX2017004715A (es)
RU (1) RU2709742C2 (es)
SG (1) SG11201702826XA (es)
TW (1) TW201619200A (es)
WO (1) WO2016057667A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
CA2992863A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
US10624974B2 (en) 2015-10-15 2020-04-21 Dingfu Biotarget Co., Ltd. Anti-OX40 antibody and application thereof
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3030647A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
RU2753493C2 (ru) 2016-12-15 2021-08-17 Эббви Байотерапьютикс Инк. Анти-ох40 антитела и их применение
JP2020504105A (ja) 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用
EP3601345A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110536703A (zh) 2017-04-20 2019-12-03 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
KR20190137847A (ko) 2017-04-20 2019-12-11 에이디씨 테라퓨틱스 에스에이 항-cd25 항체-약물 접합체와의 병용 요법
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
CN112292397B (zh) * 2017-11-24 2023-01-31 祐和医药科技(北京)有限公司 抗ox40抗体及其用途
MY195411A (en) * 2017-12-29 2023-01-19 Ap Biosciences Inc Monospecific and Bispecific Proteins With Immune Checkpoint Regulation for Cancer Therapy
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
CN111936507B (zh) * 2018-03-23 2022-11-01 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
EP3774840A1 (en) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
US20210171647A1 (en) 2018-05-11 2021-06-10 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
BR112020023746A2 (pt) * 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN111040034B (zh) * 2018-10-12 2022-08-30 广东旋玉健康生物科技有限公司 一种抗人cd358的单克隆抗体及其用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3889180A4 (en) * 2018-11-26 2023-01-04 Nanjing GenScript Biotech Co., Ltd. ANTI-OX40 HUMANIZED MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
EP3904383A4 (en) * 2018-12-25 2022-08-17 Hanx Biopharmaceutics, Inc ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
EP3946449A4 (en) * 2019-03-25 2022-11-09 Ohio State Innovation Foundation COMBINED IMMUNOREGULATION AND ITS USES
JP2022532930A (ja) 2019-05-23 2022-07-20 ブリストル－マイヤーズ スクイブ カンパニー 細胞培養培地をモニターする方法
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
US20230212291A1 (en) * 2019-11-21 2023-07-06 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
CN114746446A (zh) * 2019-11-21 2022-07-12 百济神州有限公司 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法
EP4061845A4 (en) * 2019-11-21 2023-12-13 BeiGene, Ltd. METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIM3 ANTIBODIES
EP4061844A4 (en) * 2019-11-21 2023-12-06 Beigene (Beijing) Co., Ltd. METHODS OF TREATING CANCER WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY AGENTS
WO2021098777A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230040604A1 (en) 2019-12-17 2023-02-09 Amgen Inc. Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cells
JP2023519584A (ja) 2020-03-23 2023-05-11 バイオ － テラ ソリューションズ、リミテッド 免疫細胞活性化剤の開発及び応用
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240038722A (ko) * 2021-06-29 2024-03-25 하이파이바이오 (에이치케이) 리미티드 항-ox40 모노클로날 항체 및 그의 사용 방법
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN114591988B (zh) * 2022-03-30 2023-01-13 北京贝来生物科技有限公司 一种激活肿瘤免疫的基因修饰干细胞制备方法
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
AU7603800A (en) 1999-09-24 2001-04-24 Human Genome Sciences, Inc. 32 human secreted proteins
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
RU2009135824A (ru) 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
BRPI0820875B1 (pt) * 2007-12-14 2021-10-19 Bristol-Myers Squibb Company Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira
JP5624476B2 (ja) 2008-01-18 2014-11-12 バイオ−ラッド ラボラトリーズ インコーポレーティッド アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
PE20120211A1 (es) * 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
CN107915775B (zh) * 2011-07-11 2022-07-12 伊克诺斯科学公司 结合ox40的抗体及其用途
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CA2863818A1 (en) * 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
WO2013130102A2 (en) * 2012-03-02 2013-09-06 Providence Health & Services - Oregon Dual ox40 agonist/il-2 cancer therapy methods
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe

Also Published As

Publication number Publication date
SG11201702826XA (en) 2017-05-30
JP2017532037A (ja) 2017-11-02
WO2016057667A1 (en) 2016-04-14
EP3204422B1 (en) 2022-03-30
MX2017004715A (es) 2017-06-19
AU2015328090A1 (en) 2017-04-27
ES2914177T3 (es) 2022-06-07
US20160137740A1 (en) 2016-05-19
CA2963798A1 (en) 2016-04-14
GB201517855D0 (en) 2015-11-25
RU2017115662A3 (es) 2019-05-20
JP6794348B2 (ja) 2020-12-09
EP3204422A4 (en) 2018-08-15
BR112017007170A2 (pt) 2017-12-19
US10150815B2 (en) 2018-12-11
GB2536324A (en) 2016-09-14
CN107074953A (zh) 2017-08-18
CO2017004516A2 (es) 2017-09-29
TW201619200A (zh) 2016-06-01
US20190169303A1 (en) 2019-06-06
RU2017115662A (ru) 2018-11-13
US9738723B2 (en) 2017-08-22
KR20170064550A (ko) 2017-06-09
CL2017000885A1 (es) 2017-12-15
US20180072808A1 (en) 2018-03-15
IL251537A0 (en) 2017-05-29
EP3204422A1 (en) 2017-08-16
RU2709742C2 (ru) 2019-12-19
JP2021036887A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20181018A1 (es) Anticuerpos anti-pd-1 novedosos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR105654A1 (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
PE20180926A1 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR109715A1 (es) Anticuerpos anti-cd27
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
AR106949A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
AR103713A1 (es) Anticuerpos contra tau y sus usos
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica

Legal Events

Date Code Title Description
FB Suspension of granting procedure